Literature DB >> 16168784

Advances and challenges in management of invasive mycoses.

Thomas F Patterson1.   

Abstract

Invasive mycoses pose a major diagnostic and therapeutic challenge. Advances in antifungal agents and diagnostic methods offer the potential for improved outcomes in patients with these infections, which are often lethal. Many fungal pathogens occur almost exclusively in opportunistic settings--in the immunocompromised host--and these infections are the focus of this review. Several areas of ongoing challenge remain, including the emergence of resistant organisms and the absence of reliable markers for early identification of patients at risk of developing invasive fungal disease. This Seminar reviews the changing epidemiology of invasive mycoses, new diagnostic methods, and recent therapeutic options and current management strategies for these opportunistic pathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168784     DOI: 10.1016/S0140-6736(05)67381-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

1.  A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis.

Authors:  Louis DiDone; Thomas Scrimale; Bonnie K Baxter; Damian J Krysan
Journal:  Nat Protoc       Date:  2010-05-27       Impact factor: 13.491

2.  Invasive aspergillosis in the ICU: an emerging disease.

Authors:  Wouter Meersseman; Eric Van Wijngaerden
Journal:  Intensive Care Med       Date:  2007-07-24       Impact factor: 17.440

3.  In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

Authors:  Carolina Serena; Marçal Mariné; Guillermo Quindós; Alfonso J Carrillo; J F Cano; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

4.  Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yurdanur Akgun
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

5.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.

Authors:  Jutta Auberger; Cornelia Lass-Flörl; Hanno Ulmer; Elisabeth Nogler-Semenitz; Johannes Clausen; Eberhard Gunsilius; Hermann Einsele; Günther Gastl; David Nachbaur
Journal:  Int J Hematol       Date:  2008-11-05       Impact factor: 2.490

6.  Clinical utility and development of biomarkers in invasive aspergillosis.

Authors:  Thomas F Patterson
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

7.  Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient.

Authors:  Véronique Hofman; Abdelmajid Dhouibi; Catherine Butori; Bernard Padovani; Martine Gari-Toussaint; Dea Garcia-Hermoso; Michèle Baumann; Nicolas Vénissac; Gieri Cathomas; Paul Hofman
Journal:  Diagn Pathol       Date:  2010-01-08       Impact factor: 2.644

8.  The role of galactomannan testing to diagnose invasive pulmonary aspergillosis in critically ill patients.

Authors:  Maya Hites; Eduardo Wilfrido Goicoechea Turcott; Fabio Silvio Taccone
Journal:  Ann Transl Med       Date:  2016-09

9.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 10.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.